--- title: "Korro Bio To Advance KRRO-111 As Potential Treatment For AATD" type: "News" locale: "en" url: "https://longbridge.com/en/news/287089978.md" description: "Korro Bio Inc. has chosen KRRO-111 as a candidate for clinical development to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting 3.4 million people globally. KRRO-111, a GaINAc-conjugate oligonucleotide, has shown over 90% RNA-editing success in preclinical studies. The company plans to present data on its preclinical validation. KRRO shares are currently trading at $9.32, up 1.86%." datetime: "2026-05-20T15:20:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287089978.md) - [en](https://longbridge.com/en/news/287089978.md) - [zh-HK](https://longbridge.com/zh-HK/news/287089978.md) --- # Korro Bio To Advance KRRO-111 As Potential Treatment For AATD (RTTNews) - Korro Bio Inc. (KRRO), a biopharmaceutical company, has selected KRRO-111 as a development candidate for clinical advancement in the potential treatment of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that causes the depletion of protein in the lungs and liver, leading to pulmonary emphysema and/or hepatic cirrhosis. Affecting nearly 3.4 million people worldwide, the only current FDA-approved treatment for AATD is a once-weekly infusion of human plasma-derived AAT protein called augmentation therapy. KRRO-111 is a proprietary, GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells. In preclinical studies, the drug has demonstrated successful RNA-editing by more than 90% in cells, correcting AAT transcription in liver cells. In mice models, the production of circulating M-AAT protein indicates the potential to improve lung and liver manifestations of the disease. The company plans to present data on the preclinical validation of KRRO-111 as a candidate in treating AATD. KRRO is currently trading at $9.32, up 1.86%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [KRRO.US](https://longbridge.com/en/quote/KRRO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [](https://longbridge.com/en/news/286787081.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)